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ABSTRACT
Human herpesvirus (HHV)-6, HHV-7, and cytomegalovirus (CMV) that remain latent after
primary infection can be reactivated during immunosuppression following organ transplanta-
tion in liver transplant recipients. The aim of this study was to monitor active infections for
HHV-6, HHV-7, and CMV among adult liver transplantation recipients using antigenemia
detected by an immunoperoxidase staining. Twenty-eight adult liver transplant patients were
monitored using antigenemia in blood samples obtained at the time of transplantation, as well
as weekly in the first month and once a month for 6 months. Of these patients, 28.5% showed
positive CMV antigenemia; 39.2%, HHV-6 antigenemia; and 14.2%, HHV-7 antigenemia.
The detection of the three viruses was considered to be independent of one another (P .05).
The results described above showed that few patients remain free of beta herpesviruses after
liver transplantation. Most patients were infected sequentially and not concurrently. Antigen-
emia has been considered useful to detect active HHV-6 and HHV-7 infections. Antigenemia
can be more efficiently interpreted when compared with polymerase chain reaction results,
although other studies are necessary to establish the reference of HHV-6 and HHV-7
antigenemia.CYTOMEGALOVIRUS (CMV), Human Herpesvirus(HHV 6) and HHV-7 are DNA viruseal members of the
etaherpesvirinae subfamily of the Betaherpesviridae. Betaher-
esviruses, that remain latent after primary infection can be
eactivated during immunosuppression following organ trans-
lantation.1 Active CMV infection is known as amajor infectious
complication after transplantation. HHV-6 has been related to
graft dysfunction, bone marrow suppression, and predisposition
to CMV disease, but specific aspects of HHV-7 remain poorly
studied with unknown clinical significance.1,2
Only a few studies concerning HHV-6 and HHV-7
antigenemia have been published compared with CMV.
Although the diagnosis of significant HHV-6 and HHV-7
active infections is under investigation, HHV-6 and HHV-7
antigenemia may be more efficient to discriminate between
latent and active infections compared with polymerase
chain reaction (PCR). The aim of this study was to monitor
active CMV, HHV-6, and HHV-7 infections in adult liver
transplant recipients using antigenemia techniques.
MATERIALS AND METHODS
This observational, analytic, cohort and prospective study of 35
potential liver transplant recipients between 2004 to 2006 included
28 (19 men and 9 women) subjects of overall average age of 45
years who \ill\ our inclusion criteria. The patients who died before
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Transplantation Proceedings, 43, 1357–1359 (2011)the first month after surgery or had interruption in blood sample
collection were excluded from this study.
All patients received prophylaxis for Herpes simplex infection.3
EDTA treated peripheral blood was obtained from patients at the
time of transplantation, as well as weekly for the first month and
once a month for 180 days.
The protocol was designed in accordance with the requirements
for research involving human subjects in Brazil, and approved by
the Institutional Ethics Committee (No. 430/2003). CMV antigen-
emia was performed according to Van der Ploeg et al (1992) and
HHV-6 and-7 antigenemia according to Lautenschlager (2002)
with some modifications.4,5
RESULTS
CMV antigens were detected in neutrophil nuclei and
HHV-6 and HHV-7 in lymphocyte cytoplasm (Fig 1). CMV
active infection was observed in 8/28 (28.5%) patients at a
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1358 SAMPAIO, THOMASINI, GUARDIA ET ALmedian time to first detection of 28.5 days (range 0–302).
HV-6 active infection was detected in 11/28 (39.2%)
atients with a median time to first detection of 9 days
range  0–37). HHV-7 active infection was noted in 4/28
(14.2%) patients, at a median time to first detection of 16
days (range  0–33).
Coinfections by CMV/HHV-6, CMV/HHV-7, and
HHV6/HHV-7 occurred in 4 (14.2%), 0 (0%), and 1 (3.6%)
patient, respectively. No patient had coinfection of the
three viruses at the same time.
DISCUSSION
Several data have demonstrated the importance of CMV in
the posttransplant course largerly based upon antigenemia
alone or associated with PCR tests. Among adult transplant
patients, HHV-6 and HHV-7 reactivations are frequently
demonstrated by PCR in kidney and liver transplantation
cases in association with CMV.6
Among other clinical aspects, HHV-6 may cause graft
dysfunction in liver transplant patients.7 However, HHV-6
ctive infections in immunosuppressed patients are not
ompletely clear and HHV-7 has been occasionally studied.
MV-associated syndromes, such as fever or graft dysfunc-
ion, may thus be caused by one or another of these
iruses.6
In this study, we demonstrated the appearance of CMV,
HHV-6, and HHV-7 antigenemia in the liver transplanta-
tion recipients. CMV, HHV-6, or HHV-7 was detected in
28%, 39%, or 14% of the patients, respectively. According
to other studies, CMV, HHV-6 or HHV-7 active infection
can be diagnosed based on antigen detection in peripheral
blood leukocytes from liver transplant patients by antigen-
emia (an immunocytochemical assay). Recent studies, have
shown high prevalences of this virus after liver transplanta-
tion.3,8 CMV antigens are currently detected in neutrophil
uclei while detection of HHV-6 and HHV-7 antigens
Fig 1. (A) Nuclei of the neutrophyles exhibiting positive cytom
cytoplasm exhibiting positive human herpesvirus-6 (B) and hum
00). All preparations were counterstained with Harris’s hematoxylccurs mainly in the cytoplasm of lymphocytes, due to the
iological replication characteristics of these viruses.
The antigenemia test is quite similar to that for CMV
p65 antigenemia, which is also used to diagnose active
MV infection in blood samples.9 These two tests in
parallel are helpful to diagnoses HHV-6 and CMV infec-
tions after liver transplantation.
Eight of 28 patients (28%) developed high levels of
CMVpp65 antigenemia during the first months after trans-
plantation (median  28 days). The incidence of HHV-6
antigenemia was detected in 11/28 of subjects initially at 9
days. HHV-7 antigenemia was detected in 14% of patients
at 16 days after transplantation. Our results as well as those
previously reported showed that HHV-6 appears before
CMV in most cases. HHV-6 and HHV-7 antigenemia
usually occurred together with symptomatic CMV infection
after liver transplantation. HHV-6 preceded CMV, but
HHV-7 appeared together with CMV.8 Antigenemia may
e considered a technique that is faster and easier to
erform, requiring little equipment; it is relatively easy to
nterpret. However, antigenemia always requires fresh
lood samples and cells previously fixed onto slides that can
e frozen until testing. Detection of viral antigens indicates
at there is viral replication inside the cells. It may be more
fficient to discriminate between latent and active infec-
ions. Thus, positive cells can be counted and a pattern of
ignificance level established. However, other studies are
ecessary to know the real significance of viral replication
etected by antigenemia, whereas clinical aspects of HHV-6
nd HHV-7 are not completely clear. Another advantage of
ntigenemia is that the use of immunoperoxidase staining
oes not require a fluorescence microscope. However,
ther studies are necessary to establish the use of HHV-6
nd HHV-7 antigenemia routinely after liver transplanta-
ion.
In conclusion, CMV, HHV-6, and HHV-7 were fre-
ovirus antigenemia (arrow) stained in brown. Mononuclear cell
herpesvirus-7 (C) antigenemia stained in brown (magnificationegal
anin.
CMV, HHV-6, AND HHV-7 IN LIVER RECIPIENTS 1359quently detected in among adult liver transplant patients by
antigenemia; coinfection was generally not found. This
study suppored the view that antigenemia may be useful to
detect and monitor HHV-6 and HHV-7 active infections in
liver transplant recipients.
REFERENCES
1. Tong CYW, Barkran A, Willians, et al: Association of human
herpesvirus 7 with cytomegalovirus disease in renal transplant
recipients. Transplantation 70:213, 2000
2. Ihira M, Yoshikaw T, Suzuki K, et al: Correlation between
human herpesvirus 6 and 7 infections after living related liver
transplantion. Microbiol Immunol 45:225, 2001
3. Thomasini RL, Sampaio AM, Bonon SH, et al: Detection and
monitoring of human herpesvirus 7 in adult liver transplant pa-
tients: impact on clinical course and association with cytomegalo-
virus. Transplant Proc 39:1537, 20074. Van Der Ploeg M, Van Der Berg Ap, Vlieger AM, et al:
Direct detection of cytomegalovirus in peripheral blood leukocytes.
A review of antigenemia assay and polimerase chain reaction.
Transplantation 54:193, 1992
5. Lautenschlager J, Lappalainen M, Linnavuori K, et al: CMV
infection is usually associated with concurrent HHV-6 and HHV-7
antigenemia in liver transplant Patients. J Clin Virol 25:57, 2002
6. Razonable RR, Paya CV: The impact of human herpesvirus-6
and -7 infection on the outcome of liver transplantation. Liver
Transpl 8:651, 2002
7. Lautenschlager I, Höckerstedt K, Linnavuori K, et al: Human
herpesvirus-6 infection after liver transplantation. Clin Infect Dis
26:702, 1998
8. Härmä M, Höckerstedt K, Lyytikäinen O, et al: HHV-6 and
HHV-7 antigenemia related to CMV infection after liver trans-
plantation. J Med Virol 78:800, 2006
9. Kim JM, Kim SJ, Joh JW, et al: The risk factors for
cytomegalovirus syndrome and tissue-invasive cytomegalovirus dis-
ease in liver transplant recipients who have cytomegalovirus anti-
genemia. Transplant Proc 42:890, 2010
